Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
| tau_hyperphosphorylation [2025/07/09 15:55] – [Blog Categories] administrador | tau_hyperphosphorylation [2025/07/09 15:55] (current) – [Tau hyperphosphorylation] administrador | ||
|---|---|---|---|
| Line 5: | Line 5: | ||
| from the Fudan University, Shanghai; First People' | from the Fudan University, Shanghai; First People' | ||
| published in [[Frontiers in Aging Neuroscience]] | published in [[Frontiers in Aging Neuroscience]] | ||
| - | to investigate whether activation of the δ-opioid receptor (DOR) can mitigate [[tau]] hyperphosphorylation and cellular injury in a PC12 cell model of [[Alzheimer’s disease]], and to elucidate the [[signaling pathway]]s involved. | + | to investigate whether activation of the δ-[[opioid receptor]] (DOR) can mitigate [[tau]] hyperphosphorylation and cellular injury in a PC12 cell model of [[Alzheimer’s disease]], and to elucidate the [[signaling pathway]]s involved. |
| DOR activation inhibits okadaic acid-induced tau hyperphosphorylation and neuronal [[apoptosis]] via suppression of [[CDK5]] and [[AMPK]] signaling pathways. This effect is antagonized by Naltrindole, | DOR activation inhibits okadaic acid-induced tau hyperphosphorylation and neuronal [[apoptosis]] via suppression of [[CDK5]] and [[AMPK]] signaling pathways. This effect is antagonized by Naltrindole, | ||
| ((Li J, Xu Y, Balboni G, Xia Y. A new pathway for neuroprotection against tau hyperphosphorylation via δ-opioid receptor initiated inhibition of CDK5 and AMPK signaling. Front Aging Neurosci. 2025 Jun 24; | ((Li J, Xu Y, Balboni G, Xia Y. A new pathway for neuroprotection against tau hyperphosphorylation via δ-opioid receptor initiated inhibition of CDK5 and AMPK signaling. Front Aging Neurosci. 2025 Jun 24; | ||